Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) EBIAT (2018 - 2025)

Historic EBIAT for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.

  • BioNexus Gene Lab's EBIAT rose 4730.14% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 14393.66%. This contributed to the annual value of -$1.6 million for FY2024, which is 3920.44% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported EBIAT of -$708991.0 as of Q3 2025, which was up 4730.14% from -$616172.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's EBIAT registered a high of $338744.0 during Q1 2021, and its lowest value of -$2.6 million during Q3 2023.
  • Over the past 5 years, BioNexus Gene Lab's median EBIAT value was -$103757.0 (recorded in 2024), while the average stood at -$304224.7.
  • Data for BioNexus Gene Lab's EBIAT shows a peak YoY increase of 29651.21% (in 2023) and a maximum YoY decrease of 327100.17% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's EBIAT stood at $89243.0 in 2021, then tumbled by 275.89% to -$156969.0 in 2022, then skyrocketed by 296.51% to $308463.0 in 2023, then plummeted by 212.92% to -$348319.0 in 2024, then plummeted by 103.55% to -$708991.0 in 2025.
  • Its last three reported values are -$708991.0 in Q3 2025, -$616172.0 for Q2 2025, and -$623327.0 during Q1 2025.